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Executive Summary
In the pharmaceutical industry, compounds are tested for activity against
a disease target. In a High Throughput Assay (HTA), each compound is
tested at a single concentration. In an IC50 test, a compound is tested
at a range of concentrations. Sometimes there are discrepancies between
the results of these tests and the Study Group was asked to model this.
Rather than assume normally distributed errors in the percentage effect,
the Study Group proposed a model in which there are also probabilities
p and q of a test erroneously indicating very low or high activity. The
parameters p and q can be estimated from the data, and then can be
used in the design of testing procedures.
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1 Introduction
1.1 Background and scope
(1.1.1) In this report we shall first describe the available data in Section 2, and
then propose a probabilistic model for the errors in these experiments in
Section ??. Then in Section 3.2 we shall show how the parameters in such
a model could be estimated from the data, and in Section 3.3 how such a
model could be used to improve the screening efficiency.
2 Data
2.1 General description
(2.1.1) Pfizer supplied 10 data files in csv format, each with information from
screening tests performed against a particular target. (Actually 11 were
supplied but Prog 2011-03-09.csv is identical to Prog antag 2011-03-10.csv,
and we shall refer to this data set by the latter name.) For brevity we
sometimes refer to datasets simply by the prefix, e.g. Prog antag, omitting
the date. The files vary greatly in length: in Table 1 the first 2 columns are
the file names and the number of lines in the file, and the other columns
will be explained later.
Table 1: Summary information about data files.
File name Numbers of Standard compound
lines compounds nominal commonest
Prog antag 6843 95 PF-02327888-00 PF-04723078-00
GABA 11721 431 PF-01386346-00 PF-04459758-00
iJAK 35498 1122 PF-02384554-00 PF-02563601-00
Integrase 6168 146 PF-04269440 PF-04269440-00
TrpM8 124763 2466 PF-04674115-00 PF-04674115-00
TrpA1antag 169599 2200 PF-04667541-00 PF-04840154-00
Nav1.7 138238 3966 PF-00344649-01 PF-00344649-01
Nav1.8 188342 1831 PF-00344649-01 UK-483608-01
VIF 13234 160 PF-04854474-00 PF-04854474-00
TrpA1 agonist 190309 2198 PF-04840154-00 PF-04840154-00
Each screening test is for a particular compound at a particular concen-
tration, and is measured by a percentage effect (PCE). This PCE is a nor-
malized result obtained by mapping the experimental response linearly to
a dimensionless number with the response to one control compound and
concentration, called the minimum, mapped to 0, and the response to an-
other control, called the maximum, mapped to 100. The third column in
Table 1 is the number of compounds in each file.
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(2.1.2) In general there are 2 kinds of screening trial. In one kind, called a high
throughput assay (HTA), a large number of compounds are tested, each
at a single high concentration. In the other kind, called an IC50 series, a
smaller number of compounds are tested, each at 10 or 11 concentrations,
typically spaced geometrically over 5 orders of magnitude.
(2.1.3) The data from individual experiments is controlled for quality in various
ways to ensure that nothing has gone wrong with the experiment. The
data supplied to us was selected as being cases where both HTA and IC50
data are available. That in itself is a filtering process, in that compounds
are only tested in an IC50 test if they either have shown some kind of
activity or are suspected, on pharmacological grounds, of being more likely
to be active.
2.2 HTA data
(2.2.1) The HTA tests generally involve testing a compound twice at the same
concentration. Since we are interested in the repeatability and errors
in experiments, we plotted for each filer the percentage effects for each
compound for which two percentage effects at the same concentration are
available.
(2.2.2) The results for the Prog antag data are shown in Figure 1. It is clear that
the HTA1 results are all at least about 50, and this is perhaps an example
of the filtering that may have occurred.
(2.2.3) It is also noticeable that some of the “percentage effect” values are greater
than 100%: this simply reflects the fact that the controls used are not
always the actual maximum and minimum possible. This occurs through-
out, with PCE values being both greater than 100 and less than 0: it is
simply a reminder that this normalization has taken place.
(2.2.4) The corresponding plot for the GABA file is in Figure 2. This shows a
spread of points along the diagonal, with larger errors in PCE when the
values are mid-range than when they are at the top or bottom. But it
also shows a cluster of points in the lower left corner, and another in the
upper right. So these are cases where a compound is tested twice at the
same concentration and one of the tests shows an activity close to 0 and
the other close to 100.
(2.2.5) The corresponding plots for each of the other files are also shown, in
Figures 3–10. In general they show varying degrees of association between
the different results. In the Nav1.7 data, it looks as if some filtering partly
based on whether the sum of the two HTA PCEs exceeds 60 has been
applied.
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Figure 1: Prog antag. Percentage effects in 2 HTA tests at the same
concentration. Each point represents a different compound.
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Figure 2: GABA. Percentage effects in 2 HTA tests at the same con-
centration. Each point represents a different compound.
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Figure 3: iJAK. Percentage effects in 2 HTA tests at the same con-
centration. Each point represents a different compound.
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Figure 4: Integrase. Percentage effects in 2 HTA tests at the same
concentration. Each point represents a different compound.
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Figure 5: TrpM8. Percentage effects in 2 HTA tests at the same
concentration. Each point represents a different compound.
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Figure 6: TrpA1antag. Percentage effects in 2 HTA tests at the
same concentration. Each point represents a different compound.
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Figure 7: Nav1.7. Percentage effects in 2 HTA tests at the same
concentration. Each point represents a different compound.
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Figure 8: Nav1.8. Percentage effects in 2 HTA tests at the same
concentration. Each point represents a different compound.
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Figure 9: VIF. Percentage effects in 2 HTA tests at the same con-
centration. Each point represents a different compound.
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Figure 10: TrpA1 agonist. Percentage effects in 2 HTA tests at the
same concentration. Each point represents a different compound.
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2.3 IC50 data
(2.3.1) The IC50 data is subject to more quality controls that the HTA data. In
particular a “standard” compound is used on each plate, and if the results
for the standard do not produce a satisfactory dose-response curve, then
all the values from that plate are discarded. The fact that the standard
compound is tested multiply and on different plates is of course a good
source of information about experimental error.
(2.3.2) The identifier of the standard compound in each file was given to us by
Pfizer, but was not always the identifier of the compound that occurred
most often in the data. When this happened we in fact took the standard
to be the compound whose identifier had the most IC50 points. In Table 1
the final 2 columns give the nominal standard compound, and then the
compound that had the most IC50 data points.
(2.3.3) When the dose-response curves were plotted for each file, there were clearly
anomalies. From discussion with Pfizer, we learned that in the IC50 PCE
values for Prog antag and Integrase, x should be replaced by 100− x.
(2.3.4) From further looking at the data it appeared that this also applied to the
Nav1.8 data, and that it in applied only partly to the Integrase data:
we did not replace the IC50 PCE values in lines 702–1281 of the csv file
nor lines 2372–2391 (which are both within the data for the standard
compound in those tests.) Ideally, we would like confirmation from Pfizer
that these choices are correct, and advice on any similar data-cleaning
that may need to be applied.
(2.3.5) The resulting plots of dose-response for the standard compound in each
data file are presented in Figures 11–20. In each of these, the horizontal
axis is the base-10 logarithm of the concentration. If the dose-response
model is taken as
y = d−
a− d
1 + (x/c)b
(1)
then when y is plotted against log x a tanh profile results (translated and
scaled suitably) and this is visible in all cases.
(2.3.6) Clearly there is a wide variety of different kinds of error, but the general
form is more-or-less visible throughout. For the VIF data the saturation
to 100% has not been reached even at the highest concentration used.
2.4 Comparison of HTA with IC50
(2.4.1) The percentage effect can also be compared between the HTA tests and
the IC50 tests if one of the IC50 concentrations is at, or close to, the HTA
concentration. This generally does happen and therefore allows us to pro-
duce scatter p[lots of the IC50 PCE against the HTA PCE for each file.
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Figure 11: Prog antag. IC50 test results for the standard com-
pound.
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Figure 12: GABA. IC50 test results for the standard compound.
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Figure 13: iJAK. IC50 test results for the standard compound.
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Figure 14: Integrase. IC50 test results for the standard compound.
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Figure 15: TrpM8. IC50 test results for the standard compound.
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Figure 16: TrpA1antag. IC50 test results for the standard com-
pound.
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Figure 17: Nav1.7. IC50 test results for the standard compound.
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Figure 18: Nav1.8. IC50 test results for the standard compound.
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Figure 19: VIF. IC50 test results for the standard compound.
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Figure 20: TrpA1 agonist. IC50 test results for the standard com-
pound.
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In these plots, the red points are for compounds where the HTA concen-
tration and IC50 concentration agreed exactly (to within the square root
of machine precision), the green points are where they agreed within 1%,
and the yellow within 10%. These ratios were evaluated logarithmically,
i.e. we plot yellow if 0.01 < | loge(x1/x2)| < 0.1.
(2.4.2) These plots show many features related to what we have seen before.
Figure 28 in particular shows a strong tendency for the points to fall below
the diagonal, but without falling particularly into the lower right corner.
This is most naturally interpreted as compounds whose HTA effect was
large due to measurement noise, and which then gave a lower but truer
value in the IC50 tests.
−20 0 20 40 60 80 100 120
0
20
40
60
80
100
120
HTA_PCE
IC
50
_P
CE
Prog_antag_2011−03−10.csv
0
0
0
23
42
2
5
10
269
Figure 21: Prog antag. IC50 percentage effect plotted against HTA
percentage effect at the same concentration.
3 Probabilistic error model
3.1 p,q-model
(3.1.1) In view of the cases where experiments seem to give very low effects when
we would expect high, and vice versa, it is natural to propose a model
where the errors in percentage effect do not simply have a Gaussian dis-
tribution, but also have a probability p of an error that results in a very
14
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Figure 22: GABA. IC50 percentage effect plotted against HTA per-
centage effect at the same concentration.
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Figure 23: iJAK. IC50 percentage effect plotted against HTA per-
centage effect at the same concentration.
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Figure 24: Integrase. IC50 percentage effect plotted against HTA
percentage effect at the same concentration.
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Figure 25: TrpM8. IC50 percentage effect plotted against HTA per-
centage effect at the same concentration.
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Figure 26: TrpA1antag. IC50 percentage effect plotted against HTA
percentage effect at the same concentration.
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Figure 27: Nav1.7. IC50 percentage effect plotted against HTA
percentage effect at the same concentration.
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Figure 28: Nav1.8. IC50 percentage effect plotted against HTA
percentage effect at the same concentration.
low value — a false negative, and q of an error that results in a very high
value — a false positive. We expect these both to be small, so that with
probability 1 − p − q a genuine result is obtained, but which will still be
subject to some error naturally.
(3.1.2) In discussions, Pfizer said that there can be particular experimental fail-
ures that result in both of these: a blocked tip resulting in no effect, or
carry-over resulting in possible introduction of an unwanted active com-
pound. The probabilities of these kind of events would depend on the kind
of screening that was being carried out and the nature of the reagents: it
could not be assumed to be constant for all trials.
(3.1.3) We shall here work in terms of a model in which the false negatives and
positives occur independently with probabilities p and q for each individual
experiment.
3.2 Estimating p and q
(3.2.1) To estimate p, the probability of a false negative, we need enough trials
in which we know there should be a strong activity and we need the
proportion of null effects in those trial.s One possibility is to use the HTA
and IC50 results at the same concentration. Since the quality control on
the IC50 tests is greater, we could assume that if the HTA result is low
18
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and the IC50 high, then the HTA result is a false negative of the kind
we are looking for. So the number of points near the top left corner as a
proportion of points near the top edge would be an estimate of p.
(3.2.2) Another possibility from the data we have here would be to use the IC50
tests on the standard compound for each file, and see how often the IC50
tests at high concentrations, where we can see from the general shape of
the dose-response curve that there should be strong activity, in fact show
low activity.
(3.2.3) Both of these methods have obvious problems related to the pre-filtering
of the data that has naturally occurred. For instance, the quality control
applied to the IC50 tests discards the data from a plate if the results for
the standard compound cannot be fitted reasonably well by the model.
This undoubtedly means that we are seeing the IC50 data through a se-
lection window meaning that some of the points we would like to have
seen to estimate p are not there. This is why the HTA-IC50 comparison
is preferable, since (as far as we know) the data has not been filtered on
agreement of those figures. For instance if we consider the data shown in
Figure 2 then this gives an estimate of p as about 0.2.
(3.2.4) For estimating q, the probability of a false positive, we can use similar
methods to estimate the umber of occurrences, either from the HTA-IC50
plots, or from the false positives visible at the lower end of the dose-
response curves. Those will be subject to filtering considerations similar
to those that apply to the estimation of p. However, there is also the much
more serious consideration that the true population from which those are
a sample is much larger: there are many HTA tests that correctly measure
no effect, and those have not come through into the data that we have
available here, because the compound has been ruled out and has not
gone through to the IC50 testing. However, assuming that Pfizer has full
records of the tests prior to those we have available here, the value of q can
be estimated. It will be essentially the number of points near the lower
right corner of the HTA-IC50 plot divided by the corresponding number
of trials that gave low results. We therefore expect that q will be much
less than p.
3.3 Use of this model
(3.3.1) Imagine we are screening a large number of compounds n, say of order
106, and we suspect that they may contain a small number perhaps nA =
O(102) active compounds that we wish to identify. If we do k HTA tests,
and we select the compounds that pass at least one of these for further
trial, how large should k be to ensure that we catch most of the active
compounds with high probability ?
19
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(3.3.2) The probability that an active compound is missed completely is pk, so
the expected number of active compounds missed is pknA. The actual
number of active compounds missed will be binomial, but approximately
Poisson, with this mean. So we can shoose k to control the number of
missed active compounds as we wish. In fact since nA is small, we do not
need to take k particularly large to get a low probabvility of missing any
of them.
(3.3.3) A further refinement would be to consider that tests on samples on the
same assay plate may have correlated errors that are not just independent
with probabilities p and q.
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